Acute cardiac care & resuscitationRandomised controlled trial
Impact of tocilizumab on endothelial function following out-of-hospital cardiac arrest: a substudy of the IMICA randomized controlled trial
- randomized controlled trial
- substudy
Authors' conclusion
Plasma syndecan-1 decline was less pronounced in comatose OHCA patients treated with tocilizumab, without affecting sTM or PECAM-1. This contrasts with previous IMICA findings of reduced systemic inflammation, vasopressor use, and myocardial injury, suggesting a complex relationship between inflammation and endothelial injury. Finally, PECAM-1 levels already at hospital admission had a moderate predictive value for mortality.
Study context
- Population
- Comatose resuscitated out-of-hospital cardiac arrest (OHCA) patientscomatose OHCA patients randomized in the IMICA trial
- Participants
- 80 participants
- Comparison
- tocilizumab or placebo
Primary result
As reported in the abstract
Syndecan-1 concentrations declined over time in both groups; reduction significantly less in the tocilizumab group
all P < 0.003
Further findings
Soluble thrombomodulin (sTM) and PECAM-1
- No significant between-group differences
Prediction of 30-day mortality by baseline biomarkers
- baseline PECAM-1 AUROC
- 0.71 (95% CI 0.59-0.83)
- Syndecan-1 AUROC (no predictive value)
- 0.61
- sTM AUROC (no predictive value)
- 0.53
Original publication
Summarised from the published abstract; every number is checked against it